BridgeBio’s ATTR drug Attruby posts strong Q2 sales surge as Alnylam trims Amvuttra outlook

BridgeBio Pharma reported that its transthyretin amyloidosis treatment Attruby generated $222.4 million in second‑quarter sales, more than triple the $71.5 million earned in the same period a year earlier. The figure exceeded analyst expectations of $209.2 million, underscoring a robust U.S. launch.

Analysts highlighted the growth as a sign that Attruby could reach blockbuster status, with 2026 sales projected to surpass $1 billion. The strong performance was noted as a key driver of BridgeBio's overall earnings beat for the quarter.

In contrast, Alnylam Pharmaceuticals said its competing product Amvuttra fell short of market expectations, prompting the company to lower its full‑year sales guidance. The miss was reflected in weaker revenue contributions from Amvuttra during the quarter.

The divergent results illustrate a shifting competitive landscape in the transthyretin amyloidosis market, positioning BridgeBio as the clear winner in the latest earnings season.